A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase of Trial: Phase III
Latest Information Update: 24 Dec 2019
Price : $35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms GRAPHITE
- Sponsors Takeda; Takeda Oncology
- 26 Feb 2019 Status changed from not yet recruiting to recruiting.
- 08 Jan 2019 Planned initiation date changed from 15 Nov 2018 to 28 Jan 2019.
- 11 Sep 2018 New trial record